Participated · Equity · Sep 2025

Enerside Energy focuses on the end-to-end development, construction and operation of utility-scale solar photovoltaic (PV) projects and battery energy storage systems (BESS). Its current pipeline totals 4.8 GW of solar PV capacity and 13.2 GWh of BESS, with 61 % of the projects located in Europe and a particular concentration in Italy, where it is advancing 1.2 GW of agro-voltaic parks and more than 11.2 GWh of battery projects. The company emphasizes the strategic value of the Italian assets due to their southern location and inclusion in the country’s PNIEC zones. Proceeds from the latest capital increase will underpin Enerside’s 2025-2028 Strategic Plan, which calls for investing more than €60 million over the next two years. A portion of existing reference shareholders, including the Laurion group and Alternative Green Energy (AGE), maintain meaningful participation in the business. Additional backing comes from institutional investors and family offices based in Luxembourg, Switzerland, Italy, the United Kingdom and Spain. The fresh funds strengthen the company’s balance sheet as it scales its project portfolio across Europe and other target regions.

Participated · Series C · May 2024

Aardvark Therapeutics, led by CEO Tien Lee, M.D., is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that activate innate homeostatic pathways for metabolic diseases, inflammation, and other indications. Its lead compound, oral ARD-101, is a potent bitter taste receptor (TAS2R) pan-agonist that stimulates enteroendocrine cells of the digestive tract to release multiple gut-peptide hormones including GLP-1 and the satiety hormone cholecystokinin (CCK). ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies, and based on promising clinical data the FDA has granted the drug both Orphan Drug designation and Rare Pediatric Disease designation in Prader-Willi Syndrome. The company intends to use the Series C proceeds to complete the clinical trials required for regulatory approval of ARD-101 for hyperphagia in PWS and to demonstrate ARD-101’s complementary mechanism of action to current GLP-1 therapies in the treatment of obesity. Aardvark also plans to advance other pipeline programs with the financing. The company is based in San Diego, CA. Aardvark Therapeutics, led by CEO Tien Lee, M.D., is a San Diego-based clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for metabolic diseases. Its lead compound, ARD-101, is a first-in-class small molecule TAS2R pan-agonist that demonstrated safety in Phase 1 human trials. ARD-101 has shown beneficial effects in animal models of obesity, hyperphagia, diabetes, hyperlipidemia, and inflammation. The company plans to use newly raised capital to complete three Phase 2 clinical trials of ARD-101 and to advance several potential additional formulations for major indications. Founded in 2017, Aardvark has multiple other programs in its pipeline and has already partnered one program to Sorrento Therapeutics. The company completed a $29M Series B financing to fund these activities.

Participated · Equity · Aug 2023

COMPASS Pathways develops COMP360, a proprietary synthetic psilocybin formulation delivered with psychological support to treat individuals who do not respond to current therapies. The company has earned FDA Breakthrough Therapy status and the UK ILAP designation for COMP360 in treatment‑resistant depression (TRD). It completed a phase 2b study showing significant symptom improvement with a 25mg dose and has launched the largest‑ever randomized, controlled, double‑blind phase 3 programme for TRD. COMPASS is also running phase 2 trials in PTSD and anorexia nervosa and investing in digital technology to support its therapy. The company announced a large private financing to support its clinical programmes, commercial planning and research through roughly late 2025. Compass Pathways is a London-based mental health care company focused on developing psilocybin therapy for treatment-resistant depression. Its lead program is a large-scale psilocybin therapy clinical trial being conducted at 20 sites across nine countries in Europe and North America. The company received FDA Breakthrough Therapy designation for its psilocybin therapy program in 2018. Compass intends to use the Series B proceeds to expand its lead program, support research into additional indications for psilocybin therapy, advance its preclinical pipeline, develop digital technologies, and establish new academic and clinical research partnerships. Leadership includes CEO and co-founder George Goldsmith and President, Chief Business Officer and co-founder Lars Wilde.

Participated · Series B · Jul 2023

Founded in San Francisco in 2019, MerQube provides a cloud-native, API-first platform (Garage) for creating and calculating complex, rules-based indices including options-based defined outcome products, autocallable structures, and intraday/rebalancing indices. About $27 billion in assets currently follow indices calculated on MerQube’s platform, and the company is the leading index provider for defined outcome ETFs in the U.S. Its platform supports issuance and licensing for ETFs and structured products and is being used by firms such as Calamos Investments for an autocallable ETF launching in 2025. MerQube differentiates itself by handling derivatives-linked indices that legacy index platforms cannot, while offering self-service tooling for wealth and asset managers. The company holds FCA authorisation in the U.K. and plans to expand into Europe and Asia-Pacific while enhancing AI across its systems.

Participated · Equity · Apr 2023

Axoni builds AxCore, a software platform that synchronizes data across financial institutions to reduce cost, risk, and errors when moving trade data and other critical information. The company’s technology guarantees continual, real-time replication of data with accuracy and completeness, solving coordination problems between large counterparties. Axoni has deployed or is developing solutions across cleared stock loans at OCC, global credit derivatives with DTCC, a corporate bond issuance platform with DirectBooks, global equity swaps with a consortium of market participants, and a global derivatives platform slated to launch in 2023. Since its 2017 founding, the firm has expanded its client base to include market infrastructure companies, asset managers, hedge funds, and global banks across the United States, Europe, and Asia. Led by CEO Greg Schvey, Axoni has raised more than $110M since inception and intends to use the new funds to expand operations and its business reach. Axoni provides financial market infrastructure and multi-party data networks that aim to increase efficiency, transparency, and reliability in global capital markets. Its client base includes buy-side and sell-side firms, infrastructure providers, and technology companies across the United States, Europe, and Asia. The company says applications of its technology have expanded rapidly in recent years. Axoni plans to use the new funding to expand its networks across additional asset classes and regions. Since its founding in 2013, the company has raised a total of $90 million. The firm highlights its role in driving digitalization and solving complex post-trade and capital markets infrastructure challenges. Axoni builds blockchain infrastructure, distributed-application development, and workflow-automation tools focused on multi-party data synchronization for capital markets. Founded in 2013 and based in New York, the company counts many of the world’s largest financial institutions and capital-markets infrastructure firms among its clients. Its core product suite includes AxCore, an infrastructure offering intended for mission-critical deployments, and tooling for distributed ledger applications. Axoni is developing AxLang, an Ethereum-compatible smart-contracting language designed to enable formal verification. The company plans to use recent financing to enhance its data synchronization technology, expand infrastructure products to support broader AxCore deployments, and grow the network of enterprises using distributed ledgers. Financially, Axoni has raised $59 million to date following the latest $36 million Series B. Axoni provides distributed ledger technology, bespoke smart contract development, and analytics tools tailored to capital markets participants. Its core deployments focus on post-trade data management, reference-data collaboration, and automation in derivatives processing. The company has worked with banks and market infrastructure firms to optimize post-trade workflows for credit default swaps and equity swaps. Axoni has collaborated with Citi on multiple live deployments and is engaged in projects to replatform the DTCC Trade Information Warehouse to streamline and reduce the cost of derivatives processing. It was selected as the distributed ledger provider for NEX Group's Harmony network for post-trade data management. Founded in 2013 and led by CEO Greg Schvey, Axoni has recently completed Series A financing and attracted strategic investors from both financial institutions and venture capital. Axoni is a New York-based capital markets technology firm that provides distributed ledger technology to the financial services industry. Its product offerings include distributed ledger technology deployments, bespoke smart contract development, and analytics tools. Those solutions have been implemented in partnership with more than a dozen global banks and financial infrastructure providers. Founded in 2013 and led by CEO Greg Schvey, Axoni focuses on distributed ledger infrastructure for capital markets. In December 2016 the company completed an $18m Series A financing and has raised above $20m in total funding to date. Investors include both financial institutions and venture firms, reflecting cross-sector support for its technology.